Solid Tumor Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Solid Tumor Market: By Drug Class (Antimetabolites, MAbs, Inhibitor, Mitotic Inhibitors, Multichines Inhibitors, antineoplastics), By Disease Indications ( Lung cancer, Breast cancer, Prostate cancer, Cervical cancer, Colorectal cancer, Others), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

1. Executive Summary
2. Global Solid Tumor Market Introduction
2.1. Global Solid Tumor Market – Taxonomy
2.2. Global Solid Tumor Market –Definitions
2.2.1. By Drug Class
2.2.2. By Disease Indications
2.2.3. By Region
3. Global Solid Tumor Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Solid Tumor Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Solid Tumor Market Forecast, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Antimetabolites
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. MAbs
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XPO1 Inhibitor
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Mitotic Inhibitors
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Multikinase Inhibitors
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antineoplastics
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Solid Tumor Market Forecast, By Disease Indications, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Lung cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Breast cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Prostate cancer
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Cervical cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Colorectal cancer
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Solid Tumor Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications, and Region, 2022 – 2028
8. North America Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.1.1. Antimetabolities
8.1.2. MAbs
8.1.3. XPO1 Inhibitor
8.1.4. Mitotic Inhibitors
8.1.5. Multikinase Inhibitors
8.1.6. antineoplastics
8.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Lung cancer
8.2.2. Breast cancer
8.2.3. Prostate cancer
8.2.4. Cervical cancer
8.2.5. Colorectal cancer
8.2.6. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
8.5. North America Solid Tumor Market Dynamics – Trends
9. Europe Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Antimetabolities
9.1.2. MAbs
9.1.3. XPO1 Inhibitor
9.1.4. Mitotic Inhibitors
9.1.5. Multikinase Inhibitors
9.1.6. antineoplastics
9.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Lung cancer
9.2.2. Breast cancer
9.2.3. Prostate cancer
9.2.4. Cervical cancer
9.2.5. Colorectal cancer
9.2.6. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
9.5. Europe Solid Tumor Market Dynamics – Trends
10. Asia-Pacific Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Antimetabolities
10.1.2. MAbs
10.1.3. XPO1 Inhibitor
10.1.4. Mitotic Inhibitors
10.1.5. Multikinase Inhibitors
10.1.6. antineoplastics
10.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Lung cancer
10.2.2. Breast cancer
10.2.3. Prostate cancer
10.2.4. Cervical cancer
10.2.5. Colorectal cancer
10.2.6. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Rest of Asia-Pacific
10.4. Asia-Pacific Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
10.5. Asia-Pacific Solid Tumor Market Dynamics – Trends
11. Latin America Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Antimetabolities
11.1.2. MAbs
11.1.3. XPO1 Inhibitor
11.1.4. Mitotic Inhibitors
11.1.5. Multikinase Inhibitors
11.1.6. antineoplastics
11.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Lung cancer
11.2.2. Breast cancer
11.2.3. Prostate cancer
11.2.4. Cervical cancer
11.2.5. Colorectal cancer
11.2.6. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Rest of Latin America
11.4. Latin America Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
11.5. Latin America Solid Tumor Market Dynamics – Trends
12. Middle East and Africa Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Antimetabolities
12.1.2. MAbs
12.1.3. XPO1 Inhibitor
12.1.4. Mitotic Inhibitors
12.1.5. Multikinase Inhibitors
12.1.6. antineoplastics
12.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Lung cancer
12.2.2. Breast cancer
12.2.3. Prostate cancer
12.2.4. Cervical cancer
12.2.5. Colorectal cancer
12.2.6. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Saudi Arabia
12.3.2. GCC Countries
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
12.5. MEA Solid Tumor Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott Laboratories Inc.
13.2.2. Biogen Inc.
13.2.3. AstraZeneca PLC
13.2.4. Boehringer Ingelheim GmbH
13.2.5. Amgen Inc.
13.2.6. Bristol-Myers Squibb Company
13.2.7. Stemline Therapeutics, Inc.
13.2.8. Baxter International Inc.
13.2.9. Eli Lilly and Company
13.2.10. F. Hoffmann-La Roche AG
13.2.11. GlaxoSmithKline PLC
14. Research Methodology
15. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

 

  • Abbott Laboratories Inc.
  • Biogen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Stemline Therapeutics, Inc.
  • Baxter International Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche AG

Description

1. Executive Summary
2. Global Solid Tumor Market Introduction
2.1. Global Solid Tumor Market – Taxonomy
2.2. Global Solid Tumor Market –Definitions
2.2.1. By Drug Class
2.2.2. By Disease Indications
2.2.3. By Region
3. Global Solid Tumor Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Solid Tumor Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Solid Tumor Market Forecast, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Antimetabolites
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. MAbs
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XPO1 Inhibitor
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Mitotic Inhibitors
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Multikinase Inhibitors
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antineoplastics
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Solid Tumor Market Forecast, By Disease Indications, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Lung cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Breast cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Prostate cancer
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Cervical cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Colorectal cancer
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Solid Tumor Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications, and Region, 2022 – 2028
8. North America Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.1.1. Antimetabolities
8.1.2. MAbs
8.1.3. XPO1 Inhibitor
8.1.4. Mitotic Inhibitors
8.1.5. Multikinase Inhibitors
8.1.6. antineoplastics
8.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Lung cancer
8.2.2. Breast cancer
8.2.3. Prostate cancer
8.2.4. Cervical cancer
8.2.5. Colorectal cancer
8.2.6. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
8.5. North America Solid Tumor Market Dynamics – Trends
9. Europe Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Antimetabolities
9.1.2. MAbs
9.1.3. XPO1 Inhibitor
9.1.4. Mitotic Inhibitors
9.1.5. Multikinase Inhibitors
9.1.6. antineoplastics
9.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Lung cancer
9.2.2. Breast cancer
9.2.3. Prostate cancer
9.2.4. Cervical cancer
9.2.5. Colorectal cancer
9.2.6. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
9.5. Europe Solid Tumor Market Dynamics – Trends
10. Asia-Pacific Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Antimetabolities
10.1.2. MAbs
10.1.3. XPO1 Inhibitor
10.1.4. Mitotic Inhibitors
10.1.5. Multikinase Inhibitors
10.1.6. antineoplastics
10.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Lung cancer
10.2.2. Breast cancer
10.2.3. Prostate cancer
10.2.4. Cervical cancer
10.2.5. Colorectal cancer
10.2.6. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Rest of Asia-Pacific
10.4. Asia-Pacific Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
10.5. Asia-Pacific Solid Tumor Market Dynamics – Trends
11. Latin America Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Antimetabolities
11.1.2. MAbs
11.1.3. XPO1 Inhibitor
11.1.4. Mitotic Inhibitors
11.1.5. Multikinase Inhibitors
11.1.6. antineoplastics
11.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Lung cancer
11.2.2. Breast cancer
11.2.3. Prostate cancer
11.2.4. Cervical cancer
11.2.5. Colorectal cancer
11.2.6. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Rest of Latin America
11.4. Latin America Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
11.5. Latin America Solid Tumor Market Dynamics – Trends
12. Middle East and Africa Solid Tumor Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Antimetabolities
12.1.2. MAbs
12.1.3. XPO1 Inhibitor
12.1.4. Mitotic Inhibitors
12.1.5. Multikinase Inhibitors
12.1.6. antineoplastics
12.2. Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Lung cancer
12.2.2. Breast cancer
12.2.3. Prostate cancer
12.2.4. Cervical cancer
12.2.5. Colorectal cancer
12.2.6. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Saudi Arabia
12.3.2. GCC Countries
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Solid Tumor Market – Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2022 – 2028
12.5. MEA Solid Tumor Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott Laboratories Inc.
13.2.2. Biogen Inc.
13.2.3. AstraZeneca PLC
13.2.4. Boehringer Ingelheim GmbH
13.2.5. Amgen Inc.
13.2.6. Bristol-Myers Squibb Company
13.2.7. Stemline Therapeutics, Inc.
13.2.8. Baxter International Inc.
13.2.9. Eli Lilly and Company
13.2.10. F. Hoffmann-La Roche AG
13.2.11. GlaxoSmithKline PLC
14. Research Methodology
15. Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX